Autopsy report · NCT04225676

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

“Terminated due to slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 1 year before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Acute Lymphoblastic Leukemia

Interventions

Tisagenlecleucel

Participants

5

Sites

4

Countries

United States

Trials that died the same way

• Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
  “terminated due to poor enrollment” (88% match in meaning)
• Polycystic Liver Disease in Kidney Transplant
  “Terminated due to inadequate enrollment” (87% match in meaning)
• Memantine and Antipsychotics Use
  “Study terminated due to too slow enrollment” (86% match in meaning)
• Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
  “Terminated due to lack of enrollment” (86% match in meaning)
• Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
  “Slow enrollment; study terminated.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.